1 / 76

Hong Kong Pharmaceutical Market Sample Report 2022 to 2030

This report presents a strategic analysis of the Hong Kong Pharmaceutical Market and a forecast for its development in the medium and long term.

Insights10
Download Presentation

Hong Kong Pharmaceutical Market Sample Report 2022 to 2030

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. This report presents a strategic analysis of the Hong Kong Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Hong Kong PharmaceuticalMarket , and offers unmatched value, accuracy, and expert insights

  2. Report Scope Click on the icon to know the detailed methodology

  3. Table of Content

  4. Table of Content

  5. Table of Content

  6. Table of Content

  7. Table of Content

  8. Table of Content

  9. Table of Content

  10. Table of Content

  11. Hong Kong Pharmaceutical Market 1. Pharmaceutical Market Overview

  12. 1.1 Statistics at a Glance: Pharmaceuticals in the world Prevalence of Pharmaceuticals • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In this section you will get an understanding of the topic, which includes the prevalence of Pharmaceutical, CAGR and revenue , new technology, and other details related to the topic • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Oncology Is one of the largest pharmaceutical segment which accounted for $99.5 Bn sales in 2022 $1.48 Tn Revenue from global pharmaceutical market in 2022 41,517 Plus pharmaceutical companies are registered in international directory of pharmaceutical companies 202222 6147 Pharmaceutical products were in active development from phase 1 to regulatory submission in 2022 United States Is the largest pharmaceutical market in the world accounting for 47% of the total global sales Biotech Segment is predicted to account for 35 % of spending globally in 2027 Illustrative

  13. 1.1 Statistics at a Glance: Pharmaceutical in the World (continued) Europe ~Revenue to reach $XX Bn by 2027 Asia -$XX Mn Market North America ~ Market Size of $XX Bn Hong Kong Market ~$xx Mn Market Africa ~Market Size of $XXBn Illustrative

  14. 1.2 Hong Kong Overview • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest 7.37 Bn Is the population of Hong Kong, in 2022 $429 Bn Is the Gross Domestic Product (GDP) of Hong Kong in 2022 45.3 Is the median age in Hong Kong, in 2022 $25,300 Per capita was the amount of national health expenditures in 2022 Illustrative

  15. 1.3 Economic Overview: Hong Kong Population of Hong Kong, (2020-2030) GDP of Hong Kong, (2020-2030) Population Split (2023) • In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest By Gender By Age Group 0-14 15-24 25-54 55-64 65+ Illustrative

  16. 1.4 Statistics at a Glance: Pharmaceutical in Hong Kong Prevalence of Pharmaceutical • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In this section you will get an understanding of the topic, which includes the prevalence of Pharmaceutical in Hong Kong, new technology, and other details related to the topic in Hong Kong • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Cold and Cough remedies Accounted for the highest revenue in OTC pharmaceuticals on Hong Kong in 2022 1218 Clinical trials were conducted in Hong Kong in 2022 for development of new pharmaceuticals 54.7% Market share in Hong Kong pharmaceutical market was held by proprietary medicines in 2019 $86.4 Mn Worth pharmaceutical products were exported from Hong Kong to Macau in 2021 32% Revenue in OTC pharmaceuticals market in Hong Kong was generated through online sales in 2022 $2.3 Bn Hong Kong pharmaceutical market size in 2021 Illustrative

  17. 1.5 Healthcare Scenario in Hong Kong • Hong Kong Pharmaceutical Market: The process of developing a cancer drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process: • Preclinical Research: Researchers identify potential drug candidates and test them in the lab • Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans • Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer • Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness • Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Illustrative

  18. 1.5 Healthcare Scenario in Hong Kong: Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) • Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Imaging (confirm bone related changes or respiratory problems) Initial Diagnosis Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) • Prevention and management of complications: • Stroke: Chronic transfusions, HU Genetic testing (detect the type of SCD) PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist Stakeholders Depending on the organ complications, the treatment involves different specialists at different times Illustrative

  19. 1.6 Health Insurance Coverage: Hong Kong % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage • In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year • More people had private health insurance (66%) than public coverage (35.7%) • Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) Illustrative

  20. 1.7 Budget of Hong Kong Government for Public Insurance • National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) • Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE • Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE • Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE • Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE • Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE • Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 • Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 • Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 • Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% Illustrative

  21. 1.8 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) Strategic Buyers Financial Buyers $100+ $50-$100 $25-$50 $0- $25 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative

  22. 1.8 Mergers and Acquisitions (continued) Latest Deals In Hong Kong Illustrative

  23. Hong Kong Pharmaceutical Market 2. Market Size and Forecasting

  24. 2.1 Market Size and Forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption • Hong Kong Pharmaceutical Market Forecast, 2022-2030(in $Bn) • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In this section you will get an understanding of the overall Pharmaceutical market in Hong Kong, which includes the market size, current trends and other details related to the topic • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest CAGR~ XX% Illustrative

  25. 2.2 Snapshot of Pharmaceutical Market Segmentation By Product By Therapeutic Category By Type Branded Oncology Prescription Generic Cardiovascular Diseases OTC Anti-infectives Central Nervous System Disorders Metabolic Disorders Gastrointestinal Disorders Respiratory Diseases Others • In this section you will get an understanding of the segmentations which will cover the Hong Kong Pharmaceutical Market • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report

  26. 2.2.1 Market Segmentation: By Product • Branded products are a significant component of the overall Pharmaceutical market in Hong Kong • It has the maximum market share in Hong Kong Pharmaceutical market with approximately xx% • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Hong Kong Pharmaceutical Market Share, By Product(2022)

  27. 2.2.2 Market Segmentation: By Type • Prescription Products is a significant component of the overall Pharmaceutical market in Hong Kong • It has the maximum market share in Hong Kong Pharmaceutical market with approximately xx% • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Hong Kong Pharmaceutical Market Share, By Type (2022)

  28. 2.2.3 Market Segmentation: By End User • Cardiovascular diseases, central nervous system disorders and oncology have the maximum market share in Hong Kong Pharmaceutical market with approximately xx% • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Hong Kong Pharmaceutical Market Share, By End User (2022)

  29. Hong Kong Pharmaceutical Market 3. Market Dynamics

  30. 3.1 Market growth drivers (continued) 3.1.1 Increase in export of pharmaceutical products from Hong Kong to bordering countries like China and Macau acts as a market growth driver for Hong Kong pharmaceutical market Increase in Export of Pharmaceutical Products • Increase in export of pharmaceutical products to other countries like China and Macau acts as a market growth driver for Hong Kong pharmaceutical market • $86.4 Mn pharmaceutical products were exported from Hong Kong to Macau in 2021 • Development of Guangdong-Hong Kong-Macao Greater Bay Area (GBA) where • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative

  31. 3.1 Market growth drivers (continued) 3.1.2 Growing geriatric population in Hong Kong with over 1.48 Mn population above 65 years in 2022 which is projected to reach above 1.6 Mn in 2050 Increase in Geriatric Population in Hong Kong • Geriatric population make up a significant component of the total population of Hong Kong which is also projected to increase significantly in the coming years • Geriatric individuals suffer from chronic diseases which acts as market growth driver for Pharmaceutical market in Hong Kong • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative

  32. 3.2 Market restraints 3.2.1Prevalence of Traditional Chinese Medicines in Hong Kong 3.2.2 Regulatory challenges in approval of new drugs 3.2.3 High costs of research and development of pharmaceutical products in Hong Kong • Traditional Chinese medicines are prevalent and highly accepted in Hong Kong • Drugs in Hong Kong are divided into two main categories of Chinese medicines and western medicines • This factor thus acts as a market growth restraint for acceptance of newly developed pharmaceuticals in Hong Kong • Presence of strict regulatory guidelines in registration and approval of pharmaceuticals acts as a market growth restraint • Drug office of Department of Health, government of Hong Kong is responsible for regulating the safety and efficacy of pharmaceuticals in Hong Kong • High costs of Research and development of development of pharmaceutical products are involved in Hong Kong • Pharmaceutical companies are thus shifting their Research and development plants in China thus acting as a market growth restraint to Hong Kong pharmaceutical market Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative

  33. Hong Kong Pharmaceutical Market 4. Competitive Landscape

  34. 4.1 Major Market Share Revenue of Major Players in Hong Kong Pharmaceutical Market ($ Mn) • Some of the top companies in Hong Kong Pharmaceutical Market based on revenue and market share include • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative

  35. 4.2 Key Company Profile Sino Biopharmaceutical 1 • Key Notes • Here is the list of top 10 companies which will cover in the final report • Each company will have slides for • Overview • Key details • Offerings • Name of products • Recent activities/ Press Coverage • Distribution and Vendor Partners • Mergers, Acquisitions and Collaboration • Financials • If there are specific companies that you would like to be included in the report, please let us know via email • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Lee's Pharmaceutical Holdings Limited 2 Chong Kun Dang Pharmaceutical 3 4 Hoffmann-La Roche 5 Novartis 6 GlaxoSmithKline 7 Pfizer 8 Merck & Co. 9 Sanofi AstraZeneca 10 Illustrative

  36. 4.2.1 SINO BIOPHARMACEUTICAL LIMITED Founded in: 2000 HQ: Beijing, China Type: Private Revenue: $3760 Bn Website: www.sinobiopharm.com • Sino Biopharmaceutical limited is currently the second largest pharma company in China in terms of revenue • It has above 25000 employees in 2021 and its 40 innovate drug candidates have potential to launch by 2040 • Sino Biopharmaceutical limited has more than 1400 invention patents and employees above 2700 individuals in R and D team • Sino Biopharmaceutical limited mission is science for a healthier world Therapeutic Portfolio Recent Activity / Press Coverage Illustrative

  37. 4.2.1 SINO BIOPHARMACEUTICAL LIMITED Partnerships Ecosystem Illustrative

  38. 4.2.1 DOCTOR ANYWHERE Latest Deals - Mergers and Acquisitions Illustrative

  39. 4.2.1 SINO BIOPHARMACEUTICAL LIMITED Revenues ($Bn), 2020-2030 • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Breakdown of Net Revenue by Segment, 2022 Illustrative

  40. 4.2.2 Company 2 Founded in: HQ: Type: Revenue: Website: Drugs for Cancer Recent Activity / Press Coverage Illustrative

  41. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Vendor Partners Major Distribution Partners Illustrative

  42. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Illustrative

  43. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 • Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report • In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Breakdown of Net Revenue by Segment, 2022 Illustrative

  44. Hong Kong Pharmaceutical Market 5. Reimbursement Scenario

  45. 5.1 Reimbursement Regulation in Hong Kong Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Population • The reimbursement scenario in Hong Kong nutritional supplement market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: • Public Insurance: • Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions • Medicare covers many cancer treatments, including chemotherapy, radiation therapy, and some immunotherapies • However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization • Medicaid is a joint federal-state program that provides health insurance for people with low incomes • Medicaid coverage for cancer treatments can vary by state, and may be subject to limits on the amount and type of treatment covered • Private Insurance: • Private insurance coverage for cancer treatments can also vary widely depending on the insurer and the specific policy • Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Health Insurance Coverage, 2022 Illustrative

  46. 5.1 Reimbursement Regulation in Hong Kong (continued) • Affordable Care Act: • Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover certain preventive services, including cancer screenings, without co-pays or deductibles • It also includes protections for people with pre-existing conditions, such as cancer • Reimbursement for New Treatments: • Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage • This can create challenges for companies developing and marketing new treatments • Value-Based Care: • There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments • Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics • In order to obtain access to all of the information that you are seeking, you will need to purchase the final report • Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative

  47. 5.1 Reimbursement Regulation in Hong Kong (continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) • Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid • Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities • Medicaid is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources Reimbursement Market Trends • Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs • This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative

  48. Hong Kong Pharmaceutical Market 6. Methodology & Scope

  49. Research Methodology • Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions • We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources • For forecasting, the following parameters are considered: • Market drivers and restraints along with their current and expected impacts • Technological scenario and expected developments • End use industry trends and dynamics • Trends in the consumer behavior • Regulatory scenario and expected developments • Current capacity and expected capacity additions up to 2030 • We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate • We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-sensitive, reflecting the most recent value and volume of the market across regions • All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs) • Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

More Related